tiprankstipranks
Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
PremiumRatingsCautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones
9d ago
Bluebird Bio trading resumes
Premium
The Fly
Bluebird Bio trading resumes
9d ago
Bluebird Bio trading halted, volatility trading pause
Premium
The Fly
Bluebird Bio trading halted, volatility trading pause
9d ago
Bluebird Bio price target lowered to $8 at RBC Capital on ‘limited cash runway’
PremiumThe FlyBluebird Bio price target lowered to $8 at RBC Capital on ‘limited cash runway’
2M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
2M ago
Bluebird Bio price target adjusted for stock split at Barclays
Premium
The Fly
Bluebird Bio price target adjusted for stock split at Barclays
2M ago
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
3M ago
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD
Premium
The Fly
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD
3M ago
CMS to work with Vertex, blubird to improve access to therapies, Reuters reports
Premium
The Fly
CMS to work with Vertex, blubird to improve access to therapies, Reuters reports
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100